Holen Sie sich die Stockscreener-App
25.18
1.66%
0.41
Vorhandelsmarkt:
25.23
0.05
+0.20%
Schlusskurs vom Vortag:
$24.77
Offen:
$24.86
24-Stunden-Volumen:
788.67K
Relative Volume:
1.25
Marktkapitalisierung:
$1.08B
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
17.37
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
+4.09%
1M Leistung:
+9.15%
6M Leistung:
+1.25%
1J Leistung:
+27.43%
1-Tages-Spanne:
$24.55
$25.32
1-Wochen-Bereich:
$23.63
$25.32
52-Wochen-Spanne:
$18.17
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.18 | 1.07B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Barclays Initiates Coverage of Pacira BioSciences (PCRX) with Equal-Weight Recommendation - Nasdaq
Pacira BioSciences (PCRX): Barclays Initiates Coverage with Equa - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Barclays - MarketBeat
102,668 Shares in Pacira BioSciences, Inc. $PCRX Bought by WINTON GROUP Ltd - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
EV Market: Will Pacira BioSciences Inc. stock maintain momentum in 20252025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ
Will Pacira BioSciences Inc. (82P) stock rise with strong economyQuarterly Trade Report & Real-Time Volume Analysis Alerts - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Can Pacira BioSciences Inc. (82P) stock surprise with quarterly resultsJuly 2025 Reactions & Daily Profit Focused Stock Screening - Newser
Is Pacira BioSciences Inc. (82P) stock among top earnings plays2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - Newser
Can Pacira BioSciences Inc. stock deliver surprise earnings beatWeekly Market Summary & Real-Time Price Movement Reports - Newser
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain - Finviz
Pacira Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Pacira BioSciences (PCRX) Awards Inducement Grants to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences (Nasdaq: PCRX) issues 2,200 inducement RSUs to two new employees - Stock Titan
Why Pacira BioSciences Inc. (82P) stock attracts wealthy investorsJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Pacira’s iovera° shows better outcomes than RFA for chronic back pain By Investing.com - Investing.com South Africa
Does Pacira’s ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? - Yahoo Finance
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira’s iovera° shows better outcomes than RFA for chronic back pain - Investing.com Nigeria
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain - Ortho Spine News
Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain - marketscreener.com
What macro factors could drive Pacira BioSciences Inc. (82P) stock higherWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
American Century Companies Inc. Has $28.26 Million Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
How risky is Pacira BioSciences Inc. stock now2025 Price Action Summary & Weekly Sector Rotation Insights - BỘ NỘI VỤ
(PCRX) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation in Focus Following Moves to Defend EXPAREL Patents Against Generic Competition - Sahm
Pacira down after FDA filing for generic Exparel - MSN
Pacira BioSciences (PCRX): Assessing Valuation Following Legal Win That Delays EXPAREL Generic Approvals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire
Is Pacira’s 30-Month Generic Delay for EXPAREL Shifting the Investment Outlook for PCRX? - Sahm
Pacira BioSciences Inc. Files Patent Infringement Lawsuit, Initiating 30-Month Stay of ANDA Approvals for EXPAREL® - Quiver Quantitative
Pacira BioSciences files Exparel patent infringement lawsuits against the WhiteOak Group and Qilu Pharmaceutical - marketscreener.com
Pacira BioSciences Files EXPAREL® Patent Infringement - GlobeNewswire
What analysts say about Pacira BioSciences Inc 82P stockRetail Trading Trends & Learn the Basics of Investing in 5 Days - earlytimes.in
Is Pacira BioSciences Inc a good long term investmentRSI Overbought/Oversold & Low Entry Investment Ideas - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. (82P) stock beat Nasdaq index returnsWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Pacira BioSciences, Inc. $PCRX Shares Sold by Bank of Montreal Can - MarketBeat
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsSwing Trade & Reliable Volume Spike Trade Alerts - newser.com
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Is Pacira BioSciences Inc. (82P) stock attractive for dividend growth2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Is Pacira BioSciences Inc. (82P) stock a top pick for value investorsMarket Sentiment Report & Weekly Sector Rotation Insights - newser.com
Will Pacira BioSciences Inc. stock rally after Fed decisionsJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
How Pacira BioSciences Inc. (82P) stock moves in volatile trading sessions2025 Short Interest & Fast Gaining Stock Reports - newser.com
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.87%
4.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):